Rational design of allosteric modulators: Challenges and successes

A Chatzigoulas, Z Cournia - Wiley Interdisciplinary Reviews …, 2021 - Wiley Online Library
… of targets leading to the establishment of rational design of allosteric modulators as a new
… property of the protein conformational ensemble, allosteric drug design has the potential to …

Recent trends in rationally designed molecules as kinase inhibitors

P Prasher, M Sharma, Y Chan, SK Singh… - Current Medicinal …, 2023 - ingentaconnect.com
… of rationally designed kinase inhibitors and their application in the management of malignancies.
Scheme 1 illustrates the interplay between different kinases in … kinase inhibitors [8-53]. …

Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trials

F Manetti - European journal of medicinal chemistry, 2018 - Elsevier
rationally design small molecules able to inhibit LIMK activity selectively, without affecting
other kinases. … (the so called DFG-out inactive conformation of kinases), thus providing a strong …

Trends in kinase drug discovery: targets, indications and inhibitor design

MM Attwood, D Fabbro, AV Sokolov, S Knapp… - Nature Reviews Drug …, 2021 - nature.com
… The salt bridge between αC E501 and K483 is not present in this inactive conformation. f |
Example of a type 3 inhibitor binding mode in the kinase … Strategies for rational inhibitor design

Protein allostery in rational drug design

T Kinoshita - Protein Allostery in Drug Discovery, 2019 - Springer
… The Type-I inhibitor binds to the DFG-in conformation and has no involvement in the R-spine…
-II inhibitor binds to the DFG-out conformation and the hydrophobic moiety of the inhibitor

Rational drug design of Axl tyrosine kinase type I inhibitors as promising candidates against cancer

E Sarukhanyan, S Shityakov, T Dandekar - Frontiers in Chemistry, 2020 - frontiersin.org
… In the current study, we introduce systematic computational analysis for the DFG-in conformation
of the Axl kinase to inhibit its activity using different sets of molecular docking algorithms …

In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs

Z Gagic, D Ruzic, N Djokovic, T Djikic… - Frontiers in …, 2020 - frontiersin.org
… and inactive kinase conformations … for rational design of allosteric modulators, the authors
of this study opened an exciting avenue for future discovery of novel class of kinase inhibitors

Conformation-selective analogues of dasatinib reveal insight into kinase inhibitor binding and selectivity

FE Kwarcinski, KR Brandvold, S Phadke… - ACS chemical …, 2016 - ACS Publications
… of inhibitors represent the first set of kinase inhibitors that bind the active, DFG-out inactive,
and αC-helix-out conformationskinase conformation impacts inhibitor binding and selectivity. …

Dual-target kinase drug design: Current strategies and future directions in cancer therapy

D Sun, Y Zhao, S Zhang, L Zhang, B Liu… - European Journal of …, 2020 - Elsevier
… site with DFG-in conformation, while Type II inhibitors bind to protein kinase with the DFG …
target kinase inhibitors is conducive to the rational design of a dual- or even multi-target kinase

Fragment-based drug design facilitates selective kinase inhibitor discovery

ZZ Wang, XX Shi, GY Huang, GF Hao… - Trends in Pharmacological …, 2021 - cell.com
… and bind into the highly conserved ATP binding site of kinases. The large number of PKs and
other type of ATP-binding … exhibited conserved binding conformation at the same protein [ …